Servo Controlled Oxygen Targeting Study (SCO2T)

March 11, 2022 updated by: University of Edinburgh

Randomised Cross-over Study of Servo-controlled Oxygen Targeting for Premature Infants

Most premature babies require oxygen therapy. There is uncertainty about what oxygen levels are the best. The oxygen levels in the blood are measured using a monitor called a saturation monitor and the oxygen the baby breathes is adjusted to keep the level in a target range. Although there is evidence that lower oxygen levels maybe harmful, it is not known how high they need to be for maximum benefit. Very high levels are also harmful. Saturation monitors are not very good for checking for high oxygen levels. For this a different kind of monitor, called a transcutaneous monitor, is better.

Keeping oxygen levels stable is usually done by nurses adjusting the oxygen levels by hand (manual control). There is also equipment available that can do this automatically (servo control). It is not known which is best.

Studies of automated control have shown that infants spend more time within their intended target oxygen saturation range. These have not included measurements of transcutaneous oxygen.

The investigators aim to show the transcutaneous oxygen levels as well as the oxygen saturation levels when babies have their oxygen adjusted manually or automatically.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Presently oxygen is titrated against saturation (SpO2) by manual adjustment. Automated or servo-control systems have been developed that result in tighter control of SpO2 and more time spent in the intended target range. These systems are already in clinical use. Automated systems produce quite large fluctuations in fraction of inspired oxygen (FiO2) in order to keep SpO2 in range. It is possible that this could result in short periods of high or low oxygen tension (PO2) that are undetectable using saturation monitoring. Studies to date have examined the effects of manual and automated (servo) oxygen targeting on SpO2 but not on transcutaneous oxygen tension (TcPO2).

There is a need to determine the achieved SpO2 and TcPO2 distributions associated with the use of manual and automated control as a first step in planning trials comparing these approaches over many weeks. When this is measured over a small number of hours it is not anticipated that this would have an influence on clinical outcome.

This study is a prospective, single centre, randomised crossover trial of automated (servo) control versus manual oxygen titration. Each infant will act as their own control. Infants born at less than 29 weeks gestation, greater than 48 hour of age and receiving supplementary oxygen will be eligible for inclusion.

The study will be undertaken in the Neonatal Unit at the Simpson Centre for Reproductive Health at the Royal Infirmary of Edinburgh.

Total study time is 12 hours for each infant. Infants will be randomised to commence on either automated (servo) control or manual mode. SpO2 (range 90-95%) will be continuously monitored as per normal standard of care. A second pulse oximetry probe will be place for servo control input.

Additional monitoring will be carried out as shown below:

  1. TcPO2 monitoring
  2. FiO2 monitoring
  3. Heart rate monitoring (used to validate SpO2 readings)
  4. Arterial gas sampling (only if conducted by the direct care team as part of the routine care of the infant; no extra blood samples will be taken as part of the study)

In manual mode, all oxygen adjustments will be made by clinical/nursing staff. In automated mode, oxygen will be adjusted by the respiratory support device.

In automated mode (servo control), oxygen adjustments will be made by one of two devices (depending on the clinical requirements of the baby) - the IntellO2 device (IntellO2, Vapotherm) or Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical).

SpO2 and TcPO2 readings will be downloaded directly from the multiparameter patient monitor. SpO2 will be measured using a Phillips MX500 multiparameter monitor. TcPO2 will be measured using a SenTec Digital Monitoring System with OxiVent sensor. TcPO2 is calculated by dynamic fluorescence quenching which measures oxygen molecules present in the vicinity of a fluorescent dye incorporated within the sensor surface. The sensor is operated at a constant temperature of 43 degrees Celsius. Control of sensor temperature and application duration are designed to meet all applicable standards and this monitoring device is used routinely in many neonatal units.

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Edinburgh, United Kingdom, EH16 4SA
        • The Simpson Centre for Reproductive Health, Royal Infirmary Edinburgh

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 1 month (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Infants born at less than 29 weeks gestation
  2. Infants greater than 48 hours of age
  3. Infants who are receiving supplementary oxygen
  4. Person with parental responsibility able to give consent

Exclusion Criteria:

  1. Congenital anomalies that would prevent targeting SpO2 to 90-95% (e.g. cardiac defects)
  2. Clinical condition of an infant would impair accurateTcPO2 measurement (e.g. impaired perfusion or requirement of inotropic or vasopressor support)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Servo control

Automated control of oxygen. The oxygen saturation target range will be set to 93%.

Automated oxygen control can be over-ridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets.
Other: Servo control
FiO2 adjustments will be made by one of two respiratory devices depending on the clinical requirements and current ventilatory therapy of the infant
No Intervention: Manual control
Standard practice. Oxygen adjustments will be made by clinical/nursing staff to maintain a target oxygen range of 90%-95%.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of hyperoxia and hypoxia on transcutaneous monitoring
Time Frame: 12 hours
To discover the percentage time spent within a TcPO2 range of 50mmHg (6.7kPa) - 80mmHg (10.7kPa) when infants are targeted to an SpO2 range of 90-95% using automated (servo) versus manual control.
12 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Transcutaneous oxygen variability
Time Frame: 12 hours
To discover the variability in TcPO2 (measured by standard deviation) when infants are targeted to an SpO2 range of 90-95% using automated (servo) versus manual control.
12 hours
Incidence of hyperoxia and hypoxia on saturation monitoring
Time Frame: 12 hours
To discover the percentage time spent within target SpO2 range of 90-95% when infants are targeted using automated (servo) versus manual control.
12 hours
Saturation variability
Time Frame: 12 hours
To discover the variability in SpO2 (measured by standard deviation) when infants are targeted to an SpO2 range of 90-95% using automated (servo) versus manual control.
12 hours
Fraction of inspired oxygen variability
Time Frame: 12 hours
To discover the variability in FiO2 (measured by standard deviation) when infants are targeted to an SpO2 range of 90-95% using automated (servo) versus manual control.
12 hours
Pooled frequency histogram of TcPO2
Time Frame: 12 hours
To generate a pooled frequency histogram of percentage time at a TcPO2 of below 30mmHg, 30-39.9mmHg, 40-49.9mmHg, 50-59.9mmHg, 60-69.9mmHg, 70-79.9mmHg, and 80mmHg and above for infants targeted to an SpO2 range of 90-95% using automated (servo) versus manual control.
12 hours
Pooled frequency histogram of SpO2
Time Frame: 12 hours
To generate a pooled frequency histogram of percentage time at each SpO2 point between 80 - 100% for infants targeted to an SpO2 range of 90-95% using automated (servo) versus manual control.
12 hours
Pooled frequency histogram of FiO2
Time Frame: 12 hours
To generate a pooled frequency histogram of the cumulative frequency at a FiO2 of 0.21-0.3, 0.31-0.4, 0.41-0.5, 0.51-0.6, 0.61-0.7, 0.81-0.9 and 0.91-1.0 for infants targeted to an SpO2 range of 90-95% using automated (servo) versus manual control.
12 hours
Desaturations
Time Frame: 12 hours
To discover the frequency, duration and depth of desaturations and the area (change in PO2 versus time) above and below the set PO2 threshold for infants targeted to an SpO2 range of 90-95% using automated (servo) versus manual control.
12 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Edinburgh

Collaborators

NHS Lothian

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 16, 2020

Primary Completion (Actual)

January 6, 2021

Study Completion (Actual)

January 6, 2021

Study Registration Dates

First Submitted

November 22, 2019

First Submitted That Met QC Criteria

November 22, 2019

First Posted (Actual)

November 26, 2019

Study Record Updates

Last Update Posted (Actual)

March 14, 2022

Last Update Submitted That Met QC Criteria

March 11, 2022

Last Verified

January 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AC19110

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypoxia

Clinical Trials on Servo control

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe